These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11509936)

  • 1. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A; Ohashi Y; Okamoto S; Moriyama Y; Nagao T; Kodera Y; Kanamaru A; Dohy H; Masaoka T;
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.
    Kanda J; Brazauskas R; Hu ZH; Kuwatsuka Y; Nagafuji K; Kanamori H; Kanda Y; Miyamura K; Murata M; Fukuda T; Sakamaki H; Kimura F; Seo S; Aljurf M; Yoshimi A; Milone G; Wood WA; Ustun C; Hashimi S; Pasquini M; Bonfim C; Dalal J; Hahn T; Atsuta Y; Saber W
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):744-751. PubMed ID: 26762681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
    Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
    Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-host disease. Possible higher risk for African American patients.
    Easaw SJ; Lake DE; Beer M; Seiter K; Feldman EJ; Ahmed T
    Cancer; 1996 Oct; 78(7):1492-7. PubMed ID: 8839556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease.
    Tahmaz V; Wiesen MHJ; Gehlsen U; Sauerbier L; Stern ME; Holtick U; Gathof B; Scheid C; Müller C; Steven P
    Graefes Arch Clin Exp Ophthalmol; 2021 Jan; 259(1):121-128. PubMed ID: 32812133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.
    Tzakis AG; Abu-Elmagd K; Fung JJ; Bloom EJ; Nour B; Greif F; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3225-7. PubMed ID: 1721416
    [No Abstract]   [Full Text] [Related]  

  • 7. Medication errors in paediatrics: a case report and systematic review of risk factors.
    Diav-Citrin O; Ratnapalan S; Grouhi M; Roifman C; Koren G
    Paediatr Drugs; 2000; 2(3):239-42. PubMed ID: 10937473
    [No Abstract]   [Full Text] [Related]  

  • 8. High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.
    Bacigalupo A; Van Lint MT; Sica S; Laurenti L; Rosales MB; Dominietto A; di Grazia C; Angelucci E
    Am J Hematol; 2018 May; ():. PubMed ID: 29726028
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
    Ruutu T; Gratwohl A; de Witte T; Afanasyev B; Apperley J; Bacigalupo A; Dazzi F; Dreger P; Duarte R; Finke J; Garderet L; Greinix H; Holler E; Kröger N; Lawitschka A; Mohty M; Nagler A; Passweg J; Ringdén O; Socié G; Sierra J; Sureda A; Wiktor-Jedrzejczak W; Madrigal A; Niederwieser D
    Bone Marrow Transplant; 2014 Feb; 49(2):168-73. PubMed ID: 23892326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
    Yanada M; Emi N; Naoe T; Sakamaki H; Takahashi S; Hirabayashi N; Hiraoka A; Kanda Y; Tanosaki R; Okamoto S; Iwato K; Atsuta Y; Hamajima N; Tanimoto M; Kato S
    Bone Marrow Transplant; 2004 Aug; 34(4):331-7. PubMed ID: 15220958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.
    Kanda Y; Kobayashi T; Mori T; Tanaka M; Nakaseko C; Yokota A; Watanabe R; Kako S; Kakihana K; Kato J; Tanihara A; Doki N; Ashizawa M; Kimura SI; Kikuchi M; Kanamori H; Okamoto S;
    Bone Marrow Transplant; 2016 Jan; 51(1):103-9. PubMed ID: 26437063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
    Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socié G; Solano C; Vrhovac R; Zeiser R; Kröger N; Basak GW
    Lancet Haematol; 2020 Feb; 7(2):e157-e167. PubMed ID: 32004485
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Seligson ND; Zhang X; Zemanek MC; Johnson JA; VanGundy Z; Wang D; Phelps MA; Roddy J; Hofmeister CC; Li J; Poi MJ
    Front Pharmacol; 2023; 14():1334440. PubMed ID: 38259277
    [No Abstract]   [Full Text] [Related]  

  • 16. Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Liu XL; Guan YP; Wang Y; Huang K; Jiang FL; Wang J; Yu QH; Qiu KF; Huang M; Wu JY; Zhou DH; Zhong GP; Yu XX
    Front Pharmacol; 2022; 13():891648. PubMed ID: 35873585
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.
    de Lima VJT; da Silva AF; Kerbauy LN; Kerbauy MN; Lerner D; Colares M; Ribeiro AAF; da Silva CF; Hamerschlak N; Arcuri LJ
    Ann Hematol; 2022 Aug; 101(8):1795-1802. PubMed ID: 35575911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently.
    Saraceni F; Scortechini I; Fiorentini A; Dubbini MV; Mancini G; Federici I; Colaneri FR; Lotito AF; Guerzoni S; Puglisi B; Olivieri A
    Clin Hematol Int; 2021 Dec; 3(4):153-160. PubMed ID: 34938987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
    Rodriguez N; Lee J; Flynn L; Murray F; Devlin SM; Soto C; Cho C; Dahi P; Giralt S; Perales MA; Sauter C; Ponce DM
    Transplant Cell Ther; 2021 Nov; 27(11):920.e1-920.e9. PubMed ID: 34029766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
    Loke J; Buka R; Craddock C
    Front Immunol; 2021; 12():659595. PubMed ID: 34012445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.